The conjugate outperformed single-target GEM conjugates (CD71-GEMs or CD44-GEMs) in terms of binding affinity and inhibitory efficacy, making CD71-CD44-GEMs a promising approach for treating bladder cancer by effectively targeting both cancer cells and CSCs. Here, TFRC is linked to urinary bladder carcinoma.